Therapeutic antigen recognized by expressed IgG cargo

The term "Therapeutic antigen recognized by expressed IgG cargo" refers to a functional classification of molecular targets intended for treatment via gene-encoded antibody therapies (Deal et al., 2019, Frontiers in Immunology). In this therapeutic modality, a genetic vector—such as an Adeno-associated virus (AAV), lentivirus, or mRNA—is used to deliver the coding sequence of a monoclonal IgG antibody directly into host cells (Muthumani et al., 2013, Human Vaccines & Immunotherapeutics). These cells then serve as "bio-factories" to produce and secrete the antibody into the systemic circulation or local tissue. The therapeutic antigen is the specific biological molecule—such as a viral protein (e.g., HIV gp120), a circulating cytokine (e.g., TNF-alpha), or a cell-surface receptor (e.g., HER2)—that the expressed antibody is engineered to recognize and bind (Balazs et al., 2011, Nature Biotechnology). This strategy, often termed "vectored immunoprophylaxis" or "gene-based antibody delivery," aims to provide sustained endogenous production of the therapeutic agent, potentially overcoming the limitations of traditional protein-based antibody delivery, such as the need for frequent injections and high manufacturing costs (Hollevoet et al., 2019, Journal of Biomedical Science).

Other names

Vectored antibody targetGene-encoded antibody targetDNA-encoded monoclonal antibody targetDMAb targetAAV-delivered antibody target

In vivo production of a monoclonal IgG antibody from a genetic vector (AAV, DNA, or mRNA), which subsequently binds to a specific therapeutic antigen to neutralize its function or facilitate its clearance.